India Pharma Outlook Team | Wednesday, 17 June 2026
.jpeg "India Pharma Growth Broadens as Volumes Gain Momentum")
India’s pharmaceutical market is entering a more balanced phase of growth, with rising volumes now playing a stronger role alongside pricing gains and new product introductions. This shift signals a structural change in how the market is expanding, moving beyond price-led growth to a more demand-driven trajectory.
Recent data indicates that volume growth contributed 3.2 percentage points to the Indian Pharmaceutical Market’s (IPM) 10.7 percent moving annual total (MAT) growth in May 2026, up significantly from just 0.8 percentage points a year earlier.
Price growth remained a key contributor at around 4.5 percentage points, while new product launches added roughly 3 percentage points, highlighting a well-rounded growth composition.
This evolving mix suggests that market expansion is no longer dependent on a single lever. Instead, it is being supported by a combination of increased consumption, stable pricing strategies, and continuous product innovation.
One of the most notable shifts in recent quarters has been the steady strengthening of volume growth. Over the past five quarters, volumes have consistently improved, indicating rising demand and better penetration across therapies and regions.
At the same time, contributions from new product introductions have also increased, reflecting a strong pipeline of launches and the industry’s continued focus on expanding treatment options. The alignment of these factors has created a more resilient growth pattern for the overall market.
Monthly performance further reinforces this trend. The IPM recorded year-on-year growth of 10.3 percent in April and 10.9 percent in May, with monthly sales crossing Rs 21,700 crore in both months. On a moving annual total basis, the market expanded to Rs 2.51 trillion in May, underscoring sustained momentum.
The strengthening volume trend has been closely linked to robust growth in chronic therapies, which continue to anchor market expansion. Anti-diabetic therapies grew 16.2 percent in April and 16.8 percent in May, while cardiac therapies recorded growth of 14.3 percent and 13.9 percent, respectively.
Other segments, including respiratory, neuro/CNS, anti-neoplastics, and urology therapies, also reported double-digit or near double-digit growth. This widespread performance across therapy areas indicates that demand is broad-based rather than concentrated in a few segments.
The growth in chronic therapies reflects long-term epidemiological trends, including rising incidence of lifestyle-related diseases and increased diagnosis rates, which are driving sustained demand for treatment.
A major catalyst for recent market expansion has been the rapid growth of GLP-1 therapies, particularly following the entry of generic semaglutide products after patent expiry in India.
The GLP-1 agonist market expanded sharply to Rs 1,906 crore on a moving annual total basis in May, up from Rs 565 crore a year earlier. This surge has been driven by both semaglutide and tirzepatide, making the segment one of the fastest-growing within the anti-diabetic space.
The introduction of generics has played a crucial role in this growth by improving affordability and expanding patient access. Rather than merely intensifying competition, generic semaglutide has helped enlarge the overall market by bringing more patients into treatment.
Alongside semaglutide, tirzepatide has emerged as another important growth driver, contributing to rising adoption in diabetes and obesity management.
Also Read: GLP-1 Side Effects: Tips for Gastrointestinal Comfort 2026 Update
The market’s growth momentum is also geographically widespread. South India emerged as the fastest-growing region in May, while both southern and western regions recorded strong double-digit growth in April.
Innovation continues to support this expansion, with more than 5,500 new stock-keeping units contributing around Rs 5,187 crore on a moving annual total basis. This steady stream of product launches highlights the industry’s focus on differentiation and portfolio expansion.
Additionally, several large pharmaceutical companies have reported volume growth above the industry average, indicating strong prescription traction in key therapy areas and reinforcing the demand-led nature of current growth.
The significance of the current trend lies not just in the pace of growth but in its composition. With volume, price, and new product introductions all contributing positively over the past six months, the Indian pharmaceutical market is demonstrating a healthier and more sustainable growth profile.
This balanced expansion reduces reliance on pricing alone and points to deeper market penetration, improved access, and stronger underlying demand. As these trends continue, the market appears well-positioned to sustain its growth momentum while evolving into a more mature and diversified ecosystem.
.jpg)
